Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | USP1 | O94782 | 2/20 | 0.44 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868406 | 0.88 | EGFR (0.45) | PTGS2MAPTTP53CLK4APP | |
| SCHEMBL17476607 | 0.85 | CLK4 (0.41) | PTGS2MAPTTP53CLK4APP | |
| SCHEMBL11902826 | 0.83 | CLK4 (0.53) | SCDCLK4APPDYRK1AACP1 | |
| SCHEMBL11903385 | 0.83 | EGFR (0.47) | PTGS2MAPTCLK4APPDYRK1A | |
| SCHEMBL11903033 | 0.80 | CLK4 (0.46) | SCDCLK4APPDYRK1AACP1 | |
| SCHEMBL17476604 | 0.80 | EGFR (0.45) | SCDCLK4APPDYRK1AACP1 | |
| SCHEMBL11903072 | 0.78 | CLK4 (0.44) | SCDCLK4APPDYRK1AACP1 | |
| SCHEMBL868759 | 0.78 | CLK4 (0.52) | USP1WDR48TP53CLK4APP | |
| SCHEMBL11903347 | 0.76 | FYN (0.42) | CLK4APPDYRK1AACP1EGFR | |
| SCHEMBL11903166 | 0.76 | EGFR (0.48) | CLK4DYRK1AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | PTGS2 2931/4885USP1 2634/4885WDR48 2689/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | PTGS2 2871/4885USP1 2469/4885WDR48 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.